Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
INSP 
Inspire Medical Systems Inc (INSP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: INSP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
18 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $144.53
1 Year Target Price $144.53
| 8 | Strong Buy |
| 5 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.01% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.39B USD | Price to earnings Ratio 46.14 | 1Y Target Price 144.53 |
Price to earnings Ratio 46.14 | 1Y Target Price 144.53 | ||
Volume (30-day avg) 18 | Beta 1.15 | 52 Weeks Range 73.92 - 218.52 | Updated Date 09/15/2025 |
52 Weeks Range 73.92 - 218.52 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.75 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 6.17% | Operating Margin (TTM) -1.53% |
Management Effectiveness
Return on Assets (TTM) 3.38% | Return on Equity (TTM) 8.07% |
Valuation
Trailing PE 46.14 | Forward PE 53.76 | Enterprise Value 2099587995 | Price to Sales(TTM) 2.77 |
Enterprise Value 2099587995 | Price to Sales(TTM) 2.77 | ||
Enterprise Value to Revenue 2.44 | Enterprise Value to EBITDA 30.17 | Shares Outstanding 29574300 | Shares Floating 26730746 |
Shares Outstanding 29574300 | Shares Floating 26730746 | ||
Percent Insiders 1.14 | Percent Institutions 117.62 |
Upturn AI SWOT
Inspire Medical Systems Inc
Company Overview
History and Background
Inspire Medical Systems, Inc. was founded in 2007 and is headquartered in Golden Valley, Minnesota. The company focuses on developing and commercializing minimally invasive solutions for obstructive sleep apnea (OSA). Its primary product is the Inspire system, a neurostimulation technology.
Core Business Areas
- Neurostimulation Therapy for OSA: Inspire Medical Systems develops and markets the Inspire system, a surgically implanted device for treating moderate to severe obstructive sleep apnea in patients who are unable to use or tolerate Continuous Positive Airway Pressure (CPAP).
Leadership and Structure
Todd A. Folkenberg serves as the President and Chief Executive Officer. The company has a board of directors overseeing its operations and strategy.
Top Products and Market Share
Key Offerings
- Inspire System: Inspire is the company's primary product, a neurostimulation therapy for OSA. It stimulates key airway muscles during sleep, keeping the airway open. Competitors include CPAP machines from ResMed (RMD) and Philips (PHG), and surgical procedures such as uvulopalatopharyngoplasty (UPPP).
Market Dynamics
Industry Overview
The market for sleep apnea treatments is substantial and growing due to increasing awareness of the condition and a large undiagnosed patient population. Traditional treatments include CPAP, oral appliances, and surgery.
Positioning
Inspire Medical Systems is positioned as an alternative to CPAP for patients who are unable to tolerate it. Its competitive advantage lies in its unique neurostimulation technology and clinical evidence supporting its efficacy. The company has patent protection for their device.
Total Addressable Market (TAM)
The estimated total addressable market for Inspire is several billion dollars, based on the large number of CPAP intolerant OSA patients. Inspire has significant room for growth and aims to penetrate further into the market.
Upturn SWOT Analysis
Strengths
- Innovative neurostimulation technology
- Clinical evidence supporting efficacy
- Strong patent protection
- High patient satisfaction
- Dedicated sales force and training
Weaknesses
- Surgical implantation required
- Higher upfront cost compared to CPAP
- Dependence on reimbursement approvals
- Limited patient awareness
Opportunities
- Expanding market awareness
- Gaining additional insurance coverage
- Developing new applications for neurostimulation
- Entering new geographic markets
- Technological advancements to reduce size and invasiveness
Threats
- Competition from established CPAP manufacturers
- Potential for technological disruption
- Changes in reimbursement policies
- Adverse events related to the device
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- RMD
- PHG
- SIFI
Competitive Landscape
Inspire Medical Systems' unique neurostimulation technology gives it a competitive edge in patients who don't tolerate CPAP. However, it faces competition from established players like ResMed and Philips, which have a wider range of sleep apnea solutions.
Growth Trajectory and Initiatives
Historical Growth: Inspire Medical Systems has experienced substantial growth in revenue and adoption rates over the past few years.
Future Projections: Analysts project continued revenue growth for Inspire Medical Systems due to increasing market penetration and geographic expansion.
Recent Initiatives: Recent initiatives include expanding the sales force, increasing marketing efforts, and obtaining reimbursement coverage in new regions.
Summary
Inspire Medical Systems has a novel product showing high growth. However, it's dependent on reimbursement approvals and faces competition from established competitors with larger ranges of products. They must continue to grow the product's brand while keeping costs in check. Potential for adverse events also exists and could affect future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Inspire Medical Systems Investor Relations
- SEC Filings
- Analyst Reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary depending on the source. Financial data should be verified with official company filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Inspire Medical Systems Inc
Exchange NYSE | Headquaters Golden Valley, MN, United States | ||
IPO Launch date 2018-05-03 | Founder, Chairman, CEO & President Mr. Timothy P. Herbert | ||
Sector Healthcare | Industry Medical Devices | Full time employees 1246 | Website https://www.inspiresleep.com |
Full time employees 1246 | Website https://www.inspiresleep.com | ||
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.